---
title: HUB Organoids improve preclinical toxicology, metabolism, and pharmacokinetic studies for drug discovery and development
description: Download our poster from 2021 EUROTOX virtual congress to discover how HUB Organoids are used to study drug ADME evaluation, toxicology, and PK
image: https://resources.huborganoids.nl/hubfs/patient-in-the-lab-poster-thumb.png
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# HUB Organoids applications to drug safety and ADME evaluation

### HUB Organoids improve preclinical toxicology, metabolism, and pharmacokinetic studies for drug discovery and development

Discover our latest data on the application of HUB Organoids to the preclinical evaluation of a compound safety and ADME profile.

![snapshot of 2021 Eurotox virtual congress poster depicting the application of HUB Organoids in preclinical toxicology ](https://resources.huborganoids.nl/hs-fs/hubfs/HUB%20Organoids%20improve%20preclinical%20tox%20metabolism%20and%20pharmacokinetic%20studies_snip.jpg?width=360&name=HUB%20Organoids%20improve%20preclinical%20tox%20metabolism%20and%20pharmacokinetic%20studies_snip.jpg)

Drug safety assessment at the preclinical stage is hampered by a lack of *in vitro* models that recapitulate healthy tissue physiology and gene expression for the evaluation of on- and off-target effects, drug metabolism, and pharmacokinetics (PK). Preclinical studies using animal model are costly and not always translatable to humans. On the other hand, standard patient-derived in vitro models such as primary cells have limited availability, expansion capacity, and are not stable in culture for experimental testing. Therefore there remains a need for advanced systems that can offer patient relevance and scalability to address drug toxicology, metabolism, and PK.

#### Download this poster to discover:

- Differentiated human liver organoids are promising models to study drug-induced liver injury and drug metabolism
- HUB Organoids can differentiate interspecies and regional toxicity differences as expected from *in vivo* studies
- HUB Organoids can predict toxicity of a test compound with different modes of action

### Download our poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*